Month: March 2022

On track to report topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer’s disease study in 3Q22 Conference call today at 4:30 pm Eastern time BOTHELL, Wash., March 24, 2022 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2021 and provided a clinical update. “We entered 2022 with strong momentum from the solid foundation established throughout 2021 and have made considerable progress across a number of areas key to our success,” stated Mark Litton, Ph.D., President & Chief Executive Officer of Athira Pharma. “To date, the new year...

– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH – – ENLIVEN Phase 2b NASH trial on track for topline data in first half of 2023 – – Closed enrollment in the Phase 2 ENTRIGUE trial of pegozafermin in SHTG patients with topline data expected in the second quarter of 2022 – SAN FRANCISCO, March 24, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter and full year ended December 31, 2021. “In 2021, we took important steps to advance our ongoing clinical development...

Combined Core Category Revenue of Diapers and Wipes, and Skin and Personal Care, Increased 19% Compared to Fourth Quarter of 2020; Full Year 2021 Core Category Growth Increased 13% Compared to 2020; and Company Provides Full Year 2022 Outlook and Long-Term Strategic Plan LOS ANGELES, March 24, 2022 (GLOBE NEWSWIRE) — The Honest Company (NASDAQ: HNST), a digitally native, mission-driven brand focused on leading the clean lifestyle movement, today reported fourth quarter and full year 2021 financial results for the year ended December 31, 2021. “I’m pleased we delivered our ninth consecutive quarter of year-over-year revenue growth. The power of the Honest brand remains resilient in a highly volatile environment, reflected in our strong year-over-year revenue growth of 19% for our core product categories in the fourth quarter, and...

RESTON, Va., March 24, 2022 (GLOBE NEWSWIRE) — Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced its financial results for the year ended December 31, 2021, and provided an update on the Company’s continued progress. Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, commented, “We achieved important milestones in our fuel development work in 2021 and continue to make excellent progress in executing our strategy despite war in Europe and continued impacts of the COVID-19 pandemic. Our working relationship with the U.S. government, including the Department of Energy (DOE), and its national labs, helps validate our technology in the industry and underscores the potential economic value of Lightbridge Fuel™. DOE awarded Lightbridge a second Gateway for...

Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for HERKULES-1 and Phase 1 data for FLAGSHP-1 expected in H2 2022 Robust balance sheet with cash of $459 million SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the fiscal quarter ended December 31, 2021, and provided business updates. “Erasca capped off a productive year by achieving all of our 2021 clinical and corporate milestones on or ahead of schedule,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “We initiated three HERKULES clinical...

— Company builds out management team and continues to implement its clinical programs to advance much-needed technologies for women’s health — ATLANTA, March 24, 2022 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the year ended December 31, 2021. “We are entering this year as a stronger public company with solid leadership, after strengthening both our management team as well as our board,” said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. “We are advancing our product candidates to address various underserved areas of women’s reproductive health by implementing...

Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020 Gross Profitability for Full Year 2021 Driven by Greater Market Penetration of Higher-Margin Product Mix Completed $175 Million Debt Refinancing with Hayfin Capital Management, Extending Interest-Only Period to March 2027 & Substantially Improving Company’s Cash Position Hayfin’s Partnership Supports ADMA’s Going-Forward Operations and Business Plan and Continued Exploration of Strategic Alternatives Full Year 2022 Total Revenues are Expected to Exceed $125 Million, Representing More Than a 50% Year-Over-Year Growth Rate RAMSEY, N.J. and BOCA RATON, Fla., March 24, 2022 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,...

DALLAS, March 24, 2022 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2021. “2021 was a transformational year for Vaxxinity as we completed an initial public offering and bolstered our clinical research and management teams in pursuit of our mission to disrupt the existing antibody therapy paradigm and democratize health,” said Mei Mei Hu, CEO of Vaxxinity. “In the next 12 months we expect to demonstrate our strength of execution by meaningfully advancing multiple pipeline programs through and into the clinic. We look forward to key topline readouts including UB-312 Phase 1 in Parkinson’s patients, UB-612 Phase 3 as a heterologous boost against Covid-19,...

– 2021 Marked Continued Progress with Transformation Strategy Amidst Challenging Macro-Economic Conditions – – Efforts to Scale Vehicle Acquisition Business in 2022 Remains a Priority – TAMPA, Fla., March 24, 2022 (GLOBE NEWSWIRE) — AutoWeb, Inc. (Nasdaq: AUTO), an automotive matchmaking platform connecting in-market car shoppers to their preferred vehicle transactions, is reporting financial results for the fourth quarter and full year ended December 31, 2021. “2021 marked another year of progress for our transformation strategy, despite operating against unfavorable macro-economic conditions throughout the year,” said Jared Rowe, president and CEO of AutoWeb. “Although headwinds from supply challenges across the automotive industry persisted as we closed out the year, we continued to make meaningful strides...

HighlightsPhase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma (r/r MM) patients Investigation ongoing of findings in CYAD-101-002 Phase 1b trial following announcement of clinical hold by FDA Cash position of €30.0 million ($34.0 million) as of December 31, 2021 Conference call and webcast scheduled for March 25 at 1:00 p.m. CET / 8:00 a.m. EDTMONT-SAINT-GUIBERT, Belgium, March 24, 2022 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced its financial results for the fiscal year 2021 ended December...